SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?


To: Dr. John M. de Castro who wrote (1616)11/6/1998 11:31:00 AM
From: Walter Morton  Read Replies (2) | Respond to of 2742
 
CIST is losing a major customer:

"...in Fiscal 1998, sales to three customers constituted 69% (34%, 24%, 11%) respectively of total sales. One of these customers has sold its research products business, and, as such, after the first quarter of Fiscal 1999, the Company will not have sales to this customer."

It seems that the PMC deal came just in time.



To: Dr. John M. de Castro who wrote (1616)11/6/1998 2:17:00 PM
From: Steve Harmon  Respond to of 2742
 
If Cistron's monoclonal antibody that they are testing is successful what happens to Cistron's stock then? Will it match GERN's or CTII's performance today?